Skip to Content

Davanat Approval Status

FDA Approved: No
Brand name: Davanat
Company: Galectin Therapeutics Inc.
Treatment for: Targeted Drug Delivery

Davanat is a polysaccharide polymer comprised of mannnose and galactose in development for the targeted delivery of drugs used in the treatment of cancer.

Development Status and FDA Approval Process for Davanat

DateArticle
Sep 15, 2008Pro-Pharmaceuticals Submits Data to FDA for Davanat NDA to Treat Advanced Colorectal Cancer
May 20, 2008Pro-Pharmaceuticals Announces Submission of Drug Master File forDavanat to FDA
May  1, 2008Pro-Pharmaceuticals Updates NDA Filing for Davanat
Dec 19, 2007Pro-Pharmaceuticals Selects SAFC, a Division of Sigma-Aldrich, toSubmit a Drug Master File
Jun 11, 2007Pro-Pharmaceuticals Submits Data to Begin a 505 (b)(2) Filing withthe FDA for a New Formulation of Irinotecan to be Co-administeredwith Davanat as a Functional Excipient
Apr 11, 2007Pro-Pharmaceuticals Receives Letter from the FDA for New DrugApplication for Davanat/ 5-FU
Feb  7, 2007Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of Davanat with 5-FU in Cancer Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide